Mirum Pharmaceuticals, Inc.
MIRM
$43.45
$0.912.14%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 10.00% | 16.05% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.00% | 16.05% | |||
| Cost of Revenue | 9.49% | 2.86% | |||
| Gross Profit | 10.15% | 20.68% | |||
| SG&A Expenses | 12.43% | 2.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.96% | 0.93% | |||
| Operating Income | -90.96% | 47.66% | |||
| Income Before Tax | -75.45% | 42.14% | |||
| Income Tax Expenses | -265.99% | -45.35% | |||
| Earnings from Continuing Operations | -67.12% | 42.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -67.12% | 42.22% | |||
| EBIT | -90.96% | 47.66% | |||
| EBITDA | -174.04% | 63.93% | |||
| EPS Basic | -68.04% | 42.89% | |||
| Normalized Basic EPS | -76.39% | 42.79% | |||
| EPS Diluted | -68.04% | 42.89% | |||
| Normalized Diluted EPS | -76.39% | 42.79% | |||
| Average Basic Shares Outstanding | -0.54% | 1.16% | |||
| Average Diluted Shares Outstanding | -0.54% | 1.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||